Core Insights - Amarin Corporation plc has highlighted a new post hoc analysis from the REDUCE-IT study, demonstrating that icosapent ethyl significantly reduces cardiovascular events in high-risk patients, reinforcing its role in comprehensive cardiovascular risk management [1][3]. Summary by Sections Company Overview - Amarin is a global pharmaceutical company focused on reducing the burden of cardiovascular disease and advancing cardiovascular care, with a commitment to FDA-approved therapies like VASCEPA (icosapent ethyl) [6]. Clinical Findings - The post hoc analysis from the REDUCE-IT study indicates that icosapent ethyl provides cardiovascular protection beyond standard therapies, including statins and aspirin, without additional safety concerns [5]. - Among 8,179 statin-treated participants, 6,179 (75.5%) received aspirin at baseline. Icosapent ethyl reduced major adverse cardiovascular events by 28% in aspirin users, with an absolute risk reduction of 5.9% and a number needed to treat of 17 [4]. - In the subgroup of 4,867 aspirin users, icosapent ethyl reduced total primary endpoint events by 39% [4]. Regulatory Updates - The FDA updated the labeling for fibrates, indicating no cardiovascular benefit when used with statins, emphasizing the need for effective therapies like icosapent ethyl [2]. Market Position - VASCEPA has been prescribed over 25 million times since its launch in the U.S. in January 2020, and it is covered by most major medical insurance plans [7].